# Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02242266** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 121 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium low dose
- **DRUG:** Tiotropium medium dose
- **DRUG:** Spiriva® HandiHaler® high dose
- **DRUG:** Placebo via the blue HandiHaler®
- **DRUG:** Placebo via the grey HandiHaler®

## Key facts

- **NCT ID:** NCT02242266
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-28
- **Primary completion:** 2006-06-04
- **Final completion:** —
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242266, "Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02242266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*